The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1340
A Plasma-derived Von Willebrand Factor/Factor VIII Concentrate (Wilate)
The full article is available to subscribers Subscriber Login   

The FDA has approved a new plasma-derived von Willebrand factor/Factor VIII concentrate (Wilate – Octapharma) for treatment of spontaneous and trauma-induced bleeding episodes in patients with von Willebrand disease.

THE DISEASE — Von Willebrand disease (VWD), the most common inherited bleeding disorder, can be detected in up to 1% of the general population, but is symptomatic only in about 0.01%. It is characterized by mucosal bleeding, abnormal platelet adhesion and decreased levels of von Willebrand factor (VWF) and Factor VIII (FVIII). VWF is synthesized in the endothelium and in megakaryocytes and has two roles in normal hemostasis: 1) it mediates platelet activation and adhesion in flowing blood after vascular injury and 2) it stabilizes Factor VIII, the antihemophilic clotting factor. Factor VIII is rapidly degraded in the absence of VWF.

STANDARD TREATMENT — In mild disease, ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: A Plasma-derived Von Willebrand Factor/Factor VIII Concentrate (Wilate)
Article code: 1340b
 Electronic, downloadable article - $25